Oligonucleotide Synthesis Market

Global Oligonucleotide Synthesis Market Size (2024 to 2029)

The Global Oligonucleotide Synthesis Market is expected to grow at a CAGR of 7.3% during the forecast period 2024 to 2029. The market value was at USD 6.76 billion in 2023, and the value is expected to reach USD 10.32 billion by the end of 2029.

Current Scenario of the Global Oligonucleotide Synthesis Market

The industry scenario right now involves traditional players in both the gadgets and services industry with excellent brand recognition and grown distribution passages.

Oligonucleotides are short pieces of nucleic acids that are blended with the assistance of genetic engineering and enzyme chemistry. These are generally employed in workshops for uses like therapeutic, diagnostics, and also educational, and industrial. These are employed from the start of research and screening through to the acceptance of oligonucleotide synthesis and drug production. Oligonucleotide synthesis takes place either commercially to offer assistance for different end-users or singly via DNA synthesizers for self-consumption. Nowadays, consecutive enhancements in oligonucleotide synthesis, amplification, and automation have fully revolutionized biological investigation. It is also possible to do the customizations and get the required order online easily and at the needed time. These assistances differ highly by the cost of per base pair, error rates, lengths, throughput, etc.

MARKET DRIVERS

The growing number of advancements in genetic research is propelling the global oligonucleotide synthesis market growth.

The field of genomics has been experiencing rapid progress over the last few years. Technologies such as next-generation sequencing (NGS) and genome-wide association studies (GWAS) have significantly improved the understanding of genetics. The advancements in genetic research have been facilitating the identification and manipulation of genetic sequences and resulting in the increasing demand for custom oligonucleotides. For instance, the Human Genome Project that mapped the whole human genome laid the foundation for several genetic studies and applications that depend heavily on oligonucleotide synthesis.

Y-o-Y rise in the demand for personalized medicine is further promoting the growth of the oligonucleotide synthesis market.

The adoption of personalized medicine has increased exponentially due to the improved outcomes to the patients with this approach. Using personalized medicine, the treatments are designed as per the genetic profiles of patients and such treatments are more effective compared to the traditional treatments. Throughout the globe, personalized medicine is being used to develop targeted therapies for complex diseases such as cancer. In the process of developing therapies using personalized medicine, oligonucleotides are used for diagnostics, drug development and treatment. For example, oligonucleotide-based drugs such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) are designed to target specific genetic mutations that offer precision treatment options. In the coming years, the usage and demand of personalized medicine is expected to skyrocket and the same kind of growth can be seen in the global oligonucleotide synthesis market.

Y-o-Y rise in the prevalence of genetic disorders is also contributing to the expansion of the global oligonucleotide synthesis market.

The growing patient population suffering from genetic diseases is fueling the demand for oligonucleotide synthesis as these molecules play an integral role in genetic testing, diagnostics and therapeutic applications. According to the statistics of the World Health Organization (WHO), an estimated 3% to 7% of the global population has been suffering from genetic disorders and congenital abnormalities. Genetic disorders such as cystic fibrosis, muscular dystrophy, and Huntington's disease require advanced diagnostic tools and targeted therapies and many of them require oligonucleotides. For instance, the FDA-approved drug Spinraza (nusinersen) for spinal muscular atrophy (SMA) is an antisense oligonucleotide that modulates gene expression. As per the patient population of genetic disorders increases, the demand for oligonucleotide synthesis is likely to grow and propel the global market growth.

Furthermore, factors such as the increasing number of applications of oligonucleotide synthesis in diagnostics, growing usage of oligonucleotide synthesis in the development of novel therapeutic approaches, rising investments to conduct R&D around oligonucleotide synthesis and rapid adoption of oligonucleotide-based therapies are supporting the global market. Technological advancements in synthesis methods, growing adoption of synthetic biology, increasing use of oligonucleotide synthesis in CRISPR and gene editing technologies, growing number of clinical trials involving oligonucleotides, rising demand for antisense oligonucleotides, increasing usage of oligonucleotide synthesis in forensic science are aiding the global market growth.

MARKET RESTRAINTS

High costs associated with oligonucleotide synthesis are primarily hindering the global market growth.

The production of oligonucleotides involves complex chemical processes and the use of expensive reagents and equipment, which is making them costly and giving affordability issue to many. Along with these, maintaining stringent quality control standards adding up to the cost and making them costlier further. For example, the cost of synthesizing a single oligonucleotide can range from a few hundred to several thousand dollars, which usually depends on the length and modifications required. These high costs are limiting the accessibility of oligonucleotides for smaller research labs and biotech startups and further hampering the widespread adoption and innovation in the oligonucleotide synthesis market.

In addition, factors such as complexities associated with the regulatory approval processes, limited availability of skilled professionals, technological challenges in large-scale synthesis, and the stability and delivery issues of oligonucleotides are inhibiting the growth rate of the global market. Competition from alternative technologies, limited funding for research and development, and variability in synthesis quality and consistency are also affecting the global market negatively.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Oligonucleotide Synthesis Market Analysis By Product

The oligonucleotide-based drugs segment held 32.9% of the global market share in 2023 and emerged as the most dominating segment in the global market.

The oligonucleotide-based drugs segment is also predicted to be the fastest-growing segment in the worldwide market and the growth of the oligonucleotide-based drugs segment is primarily driven by an increasing number of oligonucleotide-based drugs in clinical trials and a growing number of approvals for oligonucleotide-based drugs by FDA. For instance, as per the data of ClinicalTrials.gov, more than 150 oligonucleotide-based drugs are currently in the clinical trials phase. The growing prevalence of genetic disorders and cancer, advancements in biotechnology, and rising demand for personalized medicine are further contributing to the expansion of the oligonucleotide-based drugs segment in the global market.

The primers segment is another major segment and is projected to account for a substantial share of the global market during the forecast period. Primers are essential tools in polymerase chain reaction (PCR) and DNA sequencing. The growing demand for primers in applications such as diagnostics, research and forensic science is one of the major factors propelling the growth of the primers segment in the global market.

Global Oligonucleotide Synthesis Market Analysis By Application

The PCR segment had 33.6% of the global market share in 2023 and is expected to grow at a healthy CAGR during the forecast period.

The dominance of the PCR segment is majorly attributed to the increasing usage of PCR in molecular diagnostics, genetic research, and forensic science, increasing demand for diagnostic testing, advancements in PCR technology, and the growing prevalence of genetic disorders. For instance, according to the National Center for Biotechnology Information, PCR is used in more than 70% of molecular diagnostics labs worldwide.

The DNA synthesis segment accounted for a substantial share of the global market in 2023 and is expected to showcase a prominent CAGR during the forecast period. Factors such as Y-o-Y growth in the demand for personalized medicine, an increasing number of advancements in synthetic biology, and a growing number of R&D activities in genetic engineering are propelling the expansion of the DNA synthesis segment in the global market.

The RNAi segment is anticipated to register a promising CAGR in the global market during the forecast period. The growing use of RNAi in drug development, increasing investment in RNAi-based therapeutics, and rising advancements in delivery technologies for RNA molecules are driving the growth of the RNAi segment in the worldwide market.

The therapeutic segment is predicted to be the fastest-growing segment in the global market throughout the forecast period. An increase in the number of advancements in antisense oligonucleotide (ASO) therapies, a growing number of FDA approvals for oligonucleotide-based drugs, and rising investment in biopharmaceutical R&D are driving the growth of the therapeutic segment in the global market.

Global Oligonucleotide Synthesis Market Analysis By End-User

The academic research institutes segment occupied the major share of the global market in 2023.

The lead of the academic research institutes segment in the global market is primarily due to the ongoing genetic research, increasing funding for life sciences, the rising focus on genomics and molecular biology and growing demand for synthesized oligonucleotides for gene editing, CRISPR research, and other genetic studies.

REGIONAL ANALYSIS

North America captured 40.22% of the global market share in 2023 and stood as the most dominating region in the worldwide market.

The presence of advanced healthcare infrastructure, the availability of substantial funding to conduct R&D and the high concentration of pharmaceutical and biotechnology companies have been majorly favoring the North American region to register dominance in the global market. Y-o-Y rise in the prevalence of genetic disorders and increasing demand for personalized medicine are further propelling the North American market. As per the data of the Biotechnology Innovation Organization, the number of biotechnology companies have been gradually growing in the North American region and is expected to result in the increasing demand for oligonucleotide synthesis.

The Asia-Pacific region is predicted to register the fastest growth in the global market during the forecast period. Factors such as increasing investments in the healthcare industry, rapid growth in the biotechnology sector, growing adoption of advanced diagnostic technologies, rising focus on improving healthcare infrastructure, and increasing R&D activities are driving the expansion of the oligonucleotide synthesis market in the Asia-Pacific region. For instance, as per the data of Nature, China invested USD 9 billion in biotechnology research in 2023. The number of biotechnology startups in India is growing at a promising pace. These statistics indicate that the demand for oligonucleotide synthesis is expected to rise in the Asia-Pacific region and boost the regional market growth.

Europe is a key regional segment for oligonucleotide synthesis and is projected to hold a substantial share of the global market during the forecast period. The growing number of R&D activities, an increasing number of initiatives from the governments of European countries in favor of biotechnology, rising focus on the advancements in the pharmaceutical industry, the commitment of Europe to precision medicine, and increasing investment in genetic research are driving the oligonucleotide synthesis market in Europe. According to the data of the European Commission, the European Union invested 2 billion Euros in genomic research and related fields in 2023.

KEY MARKET PLAYERS

The major key players in the global oligonucleotide synthesis market are Agilent Technologies, Inc. (US), ATDBio Ltd. (UK), Bio-Synthesis, Inc. (US), BioAutomation Corporation (US), LGC Biosearch Technologies (US), Biogen International (US), Sarepta Therapeutics (US), Eurofins Genomics (Germany), Eurogentec (Belgium), GeneDesign, Inc. (Japan), GE Healthcare (US), GenScript, Inc. (US), Integrated DNA Technologies (IDT, US), Nitto Denko Avecia, Inc. (US), and others.

RECENT HAPPENINGS IN THE MARKET

• Dalton Pharma Services has declared the fulfillment of its Oligonucleotide Production Suite. The Oligonucleotide Production Suite comprises the most recent technology that allows small to large-scale production and purification capability of Oligo. Special controls, including environmental (for instance, HEPA-filtered air) and making controls have been executed.
• Biolytic Lab Performance Inc. developed Dr. Oligo 48, a new 48-column rotor synthesizer to enhance overall performance aspects like quality, speed, and price. Biolytic Lab Performance, Inc.

DETAILED SEGMENTATION OF THE GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET INCLUDED IN THIS REPORT

This research report on the global oligonucleotide synthesis market has been segmented and sub-segmented based on product, end-user, and region.

By Product

• Oligonucleotide-Based Drugs
• Primers
• Probes
• Large-Scale Synthesized Oligos
• Intermediate-Scale Synthesized Oligos
• Linkers & Adaptors

By End-user

• Academic Research Institutes
• Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Hospitals

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa